|
|
1000 Marina Blvd., Suite 300
Brisbane, CA 94005 USA
phone:(650) 616-2200
fax:(650) 616-2222
|
|
| Symbol |
CLGY |
| Exchange |
|
| Founded |
1989 |
| Employees |
50 |
|
|
| www.cellegy.com
|
|
| Research Sector |
Biotech Specialty Pharma |
|
 |
| Summary Description |
| Dugs for gastroenterology conditions & sexual dysfunction using nitric oxide donor technologies. |
|
| Management |
| CEO: K. Michael Forrest CFO: A. Richard Juelis |
| |
|
|
|
|
|
|
| Recent Results |
| Financings Initial Public Offering (8/95): $8.2 Million Private Placement (4/96): $7.5 Million Private Placement (7/97): $3.8 Million Secondary Offering (11/97): $15.1 Million Private Placement (7/99): $10.1 Million Private Placement (10/00): $11.6 Million Private Placement (6/01): $15.4 Million Private Placement (11/02): $5.5 Million |
| |
|
|
|
|
| Keywords |
| skin care, biotech, Urology, prostate, urinary, bladder, erectile cancer, sexual dysfunction, menopause, Restless Leg Syndrome, Raynaud's Disease, hypogonadism, hemorrhoids, nitric oxide |
|
|
|
| Description |
|
Cellegy Pharmaceuticals, Inc. is a specialty biopharmaceutical company engaged in the development of prescription drugs and skin care products. The Company also develops and commercializes prescription drugs targeting primarily gastroenterology conditions, sexual dysfunction of both men and women, and selected conditions affecting women's health using proprietary topical formulations and nitric oxide (NO) donor technologies. |
|
| Products / Services |
The Company's prescription products are directed toward the treatment of gastrointestinal disorders, sexual dysfunction of both men and women and selected conditions affecting women's health. Cellegy's lead product candidate, Tostrex gel, is for the treatment of male hypogonadism, which usually results in diminished sexual function, lethargy and, in severe cases, reduced bone and muscle mass in men. The Company has completed patient enrollment in its Phase III study using Cellegesic for the treatment of chronic anal fissures and hemorrhoids. The company also began Phase II trials of Tostrelle, a product designed to restore normal testosterone levels in menopausal women. Cellegy has completed development of certain consumer skin care and cosmeceutical products, including skin barrier repairing/fortifying moisturizers and anti-aging lotions and creams.
|
|
| Technology / Differentiation |
| Cellegy has developed expertise and a product pipeline using nitroglycerin ointment and nitric oxide donors to address a number of serious medical conditions, including female sexual dysfunction, Raynaud's Disease, prostate cancer, and Restless Leg Syndrome. |
|
| Market / Customers |
Wherever possible, the Company plans to self market its products to a targeted audience of key physical specialists, including Gastrocaterologists and Obstetrician-Gynecologists through the establishment of its own sales force. The company, along with its marketing partner, PDI, Inc., currently is in discussions with the FDA to determine requirements for marketing approval of Fortigel 2.0% for the treatment of male hypogonadism. The Company is marketing its C79 Intensive Moisturizer formulation to a major specialty retailer that incorporates C79 into hand cream products.
|
|
| Competitors / Substitutes / Alternatives |
Competitors in the pharmaceutical industry include Solvay SA, Watson Pharmaceuticals Inc and Wyeth
|
|
| Strategy |
The Company intends to become a leader in the development and marketing of selected specialty biopharmaceutical products through the following elements of its business and commercialization stratgey: self marketing to specialty physician markets in the US, being responsible for the marketing infrastructure contained with the Company's PDI Pharmaceutical Products Group overseas (particularly in Europe), acquiring complementary products and companies consistent with its commercial objectives, and entering into manufacturing and distribution agreements with overseas markets.
|
|
| Funding |
| Cellergy completed its $8.2 Million initial public offering in Aug. 1995, with 5.5 Million Private Placement in Nov, 2002. The company had $__M working capital at the end of 2002. |
|
| Status |
| Cellegy Pharmaceuticals, Inc. announced that a preliminary analysis of a recently completed Phase 3 clinical trial shows that its lead product candidate, Cellegesic (nitroglycerin ointment, 0.4%), produced a statistically significant (p<0.05) reduction in anal fissure pain in comparison to a placebo control during the first three weeks of the trial, the primary efficacy endpoint of the study. As observed in earlier trials, the most common side effect was mild to moderate headache. |
|
|
|
| |
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members
